Cover Image
市場調查報告書

EpiCast Report:全球大腸癌的流行病學的預測

EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 258691
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:全球大腸癌的流行病學的預測 EpiCast Report: Colorectal Cancer - Epidemiology Forecast to 2023
出版日期: 2014年12月01日 內容資訊: 英文 54 Pages
簡介

大腸癌是男性第三、女性第二高發病率的癌症。而全球各國的發病率及得病率都有增加的趨勢。主要9個國家的整體發病數量預測將從2012年的123萬件,增加到2020年的175萬件,以年平均4.22%的速度擴大。市場雖然依年齡結構、男女性別、癌症診斷階段·診察計劃等而有所不同,但所有市場都以切除患部為最普及的治療法,70∼90%的患者接受消除手術。

本報告提供全球主要9個國家的大腸癌症患病情形與今後預測相關分析,提供大腸癌的特徵,各國的情形,今後10年的發病率·盛行率預測值等調查評估,並將其結果為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 背景
  • 風險要素和共生病症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測前提條件
  • 流行病學的預測(今後10年份)
    • 大腸癌的整體發病數量
    • 特定年齡層的大腸癌發病數量
    • 男女的大腸癌發病數量
    • 年齡調整罹患率
    • 診斷時的分期
    • 5年患病人數
    • 5年患病人數的KRAS 現狀
  • 議論

第4章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER006-14

Colorectal cancer (CRC) is cancer that starts in the colon or the rectum. CRC has the third highest incidence among all cancers in men and second highest in women. CRC is a high mortality cancer, with mortality rates just behind lung, liver, and stomach cancers in men, and breast and lung cancers in women. Most cases of CRC start as small adenoma polyps in the inner lining of the colon or rectum. CRC screening aims to identify and remove polyps when they are small to prevent the polyps from changing into cancer and has been shown to be effective in reducing the mortality from CRC.

GlobalData epidemiologists forecast that the number of total diagnosed incident cases of CRC in the 8MM is expected to grow from 758,062 cases in 2013 to 1,016,937 cases in 2023 at a rate of 3.41% per year during the forecast period. The number of diagnosed prevalent cases in the 8MM is expected to increase by 34.1% over the next decade from 2,583,156 cases in 2013 to 3,464,998 cases in 2023.

GlobalData's forecast and analysis is supported by at least 10 years of historical data obtained from international cancer organizations, country-specific government sources, and peer-reviewed studies. The forecast of incident CRC cases were based on detailed age-specific and sex-specific trends in incidence in each of the 8MM. This forecast provides detailed case-segmentation of the CRC pool for each country by age, sex, stage at diagnosis; prevalent cases are further segmented by KRAS mutation status, thereby providing a comprehensive view of CRC epidemiology in 8MM. The forecast is driven by a thorough analysis of historical data and current events such as screening initiatives and by the projected population growth in each country. The forecast methodology was also consistent across all eight markets, thereby allowing for a meaningful comparison among them.

Scope

  • The colorectal cancer (CRC) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for CRC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). In addition, the report also includes a 10-year epidemiological forecast for the diagnosed incident cases of CRC and diagnosed five-year prevalent cases in these markets from 2013-2023. The diagnosed incident cases of CRC are further segmented by age (20-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and =80 years), sex, stage at diagnosis, and KRAS mutation status.
  • The CRC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global CRC market.
  • Quantify patient populations in the global CRC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups, sex, stage at diagnosis, and KRAS mutation status that present the best opportunities for CRC therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. 8MM, Incidence Trends
    • 3.3.2. 8MM, Five-Year Relative Survival
    • 3.3.3. 8MM, Screening Programs for CRC
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of CRC (2013-2023)
    • 3.5.1. Diagnosed Incident Cases of CRC
    • 3.5.2. Age-Specific Diagnosed Incident Cases of CRC
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of CRC
    • 3.5.4. Age-Standardized Incidence
    • 3.5.5. Cancer Stage at Diagnosis
    • 3.5.6. Diagnosed Five-Year Prevalent Cases of CRC
    • 3.5.7. KRAS Status among Diagnosed Five-Year Prevalent Cases of CRC
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Acting Global Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for CRC
  • Table 2: 8MM, Five-Year Relative Survival
  • Table 3: 8MM, Sources of CRC Incidence Data
  • Table 4: 8MM, Sources of CRC Diagnosed Five-Year Prevalent Cases Data
  • Table 5: 8MM, Sources of CRC Cancer Stage at Diagnosis Data
  • Table 6: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 7: 8MM, Age-Specific Diagnosed Incident Cases of CRC, Both Sexes, N, Row (%), 2013
  • Table 8: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, Ages ≥20 Years, 2013
  • Table 9: 8MM, Diagnosed Five-Year Prevalent Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 10: 8MM, KRAS Status among CRC Prevalent Cases, 2013

List of Figures

  • Figure 1: Historical Age-Adjusted CRC Incidence (Cases per 100,000 Population) in 8MM, Men, 1998-2007
  • Figure 2: Historical Age-Adjusted CRC Incidence (Cases per 100,000 Population), in 8MM, Women, 1998-2007
  • Figure 3: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of CRC, Both Sexes, N, 2013
  • Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, Ages ≥20 Years, 2013
  • Figure 6: 8MM, Age-Standardized Incidence of CRC (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013.
  • Figure 7: 8MM, Cancer Stage at Diagnosis Percentage Distribution, Ages ≥20 Years.
  • Figure 8: 8MM, Diagnosed Five-Year Prevalent Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
Back to Top